Results 51 to 60 of about 190,686 (266)

Olink Proteomics Analysis Reveals Heterogeneous Responses to FcRn Blockade in Anti‐AChR Antibody‐Positive Myasthenia Gravis: FGF‐19 as a Novel Biomarker

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective This study aimed to systematically observe the clinical manifestations, immune cell subsets, and dynamic changes in serological indicators in patients with myasthenia gravis (MG) before and after efgartigimod (EFG) treatment. Methods We analyzed the baseline data, laboratory parameters, and lymphocyte subset proportions in MG ...
Tiancheng Luo, Deyou Peng, Zhouao Zhang, Mingjin Yang, Xinyan Guo, Tianyu Ma, Xiaoyu Huang, Mingming Xu, Linlin Fu, Yong Zhang   +9 more
wiley   +1 more source

Will Memantine Exacerbate Seizures in People With Epilepsy? A Prospective Cohort Study

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To evaluate whether add‐on memantine would exacerbate seizures in people with epilepsy. Methods This was a prospective cohort study. People with epilepsy diagnosed with cognitive impairment were consecutively invited. Those who agreed were followed up for at least 24 weeks.
Peiyu Wang, Lu Lu, Hui Gao, Qi Zhang, Jing Xiao, Josemir W. Sander, Weixi Xiong, Dong Zhou   +7 more
wiley   +1 more source

Discovery and Targeted Proteomic Studies Reveal Striatal Markers Validated for Huntington's Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Clinical trials for Huntington's disease (HD) enrolling persons before clinical motor diagnosis (CMD) lack validated biomarkers. This study aimed to conduct an unbiased discovery analysis and a targeted examination of proteomic biomarkers scrutinized by clinical validation. Methods Cerebrospinal fluid was obtained from PREDICT‐HD and
Daniel Chelsky, Cara Joyce, H. Jeremy Bockholt, Paul A. Rudnick, William H. Adams, Fiona McAllister, Justin W. Smock, Michael A. Newton, Jane S. Paulsen   +8 more
wiley   +1 more source

Where, How, and How Much? A Multicenter Cohort Study of the Relationship Across Lupus Decision‐Aid Modality, Place of Administration, Interruption and Viewing Completeness, and Patient‐Reported Outcomes

Arthritis Care &Research, EarlyView.
Objective We assessed whether shared decision‐making (SDM) and patient acceptability, feasibility, and overall satisfaction with a computerized patient decision aid (PtDA) for patients with systemic lupus erythematosus (SLE) differs by PtDA setting, modality, and the viewing experience. Methods Patients with SLE were invited to view a self‐administered
Jasvinder A. Singh, Mark Beasley, Larry R. Hearld, for the Implementing Decision‐Aid for Lupus in Clinics (IDEAL) Consortium, Winn Chatham, Jasvinder Singh, Sonali Narain, Narender Annapureddy, Diane Kamen, Kimberly Trotter, Vikas Majithia, Cathy Ching, Zineb Aouhab, Swamy Venturupalli, Rosalind Ramsey‐Goldman, Alfred Kim, Maureen McMahon, Sam Lim, Kalpana Bhairavarasu, Alexa Meara, Kenneth Kalunian   +20 more
wiley   +1 more source

Software Defined Networking With Pseudonym Systems for Secure Vehicular Clouds

IEEE Access, 2016
The vehicular cloud is a promising new paradigm, where vehicular networking and mobile cloud computing are elaborately integrated to enhance the quality of vehicular information services.
Xumin Huang, Rong Yu, Jiawen Kang, Ning Wang, Sabita Maharjan, Yan Zhang   +5 more
doaj   +1 more source

​Did a Non‐Medical Biosimilar Switching Policy Cause an Increase in Non‐Biologic/Biosimilar Health Care Resource Utilization or Cost in Patients With Inflammatory Arthritis?

Arthritis Care &Research, EarlyView.
Objective This study aimed to evaluate the impact of a series of policies that mandated switching patients with inflammatory arthritis (IA) from an originator biologic to a biosimilar in British Columbia, Canada, on health care resource use and cost.
HaoHung Dang, Sandra Blitz, Nick Bansback, Michael Law, Mark Harrison   +4 more
wiley   +1 more source

A Scoping Review on Artificial Intelligence–Supported Interventions for Nonpharmacologic Management of Chronic Rheumatic Diseases

Arthritis Care &Research, EarlyView.
This review summarizes artificial intelligence (AI)‐supported nonpharmacological interventions for adults with chronic rheumatic diseases, detailing their components, purpose, and current evidence base. We searched Embase, PubMed, Cochrane, and Scopus databases for studies describing AI‐supported interventions for adults with chronic rheumatic diseases.
Nirali Shah, Alexis Castellanos, Yen Chen, John Piette, Amy Bucher, Susan Murphy   +5 more
wiley   +1 more source

Study on utility optimization for randomized response mechanism

Tongxin xuebao, 2019
For the study of privacy-utility trade-off in local differential privacy,the utility optimization models of binary generalized random response mechanism for the case of differential privacy and approximate differential privacy were established.By graphic
Yihui ZHOU, Laifeng LU, Zhenqiang WU
doaj   +2 more sources

Service Outsourcing Character Oriented Privacy Conflict Detection Method in Cloud Computing

Journal of Applied Mathematics, 2014
Cloud computing has provided services for users as a software paradigm. However, it is difficult to ensure privacy information security because of its opening, virtualization, and service outsourcing features.
Changbo Ke, Zhiqiu Huang, Weiwei Li, Yi Sun, Fangxiong Xiao   +4 more
doaj   +1 more source

Differential Privacy for Coverage Analysis of Software Traces

, 2021
Yu Hao, Sufian Latif, Hailong Zhang, Raef Bassily, Atanas Rountev   +4 more
openalex   +2 more sources